Multilayered proteomics reveals that JAM‐A promotes breast cancer progression via regulation of amino acid transporter LAT1

Abstract

AbstractRecent studies have shown that transmembrane‐type tight junction proteins are upregulated in various cancers compared with their levels in normal tissues and are involved in cancer progression, suggesting that they are potential therapeutic targets. Here, we demonstrated the expression profile and a novel role of junctional adhesion molecule‐A (JAM‐A) in breast cancer. Immunohistochemistry of surgical specimens showed that JAM‐A was highly expressed from carcinoma in situ lesions, as in other adenocarcinomas, with higher expression in invasive carcinomas. High expression of JAM‐A contributed to malignant aspects such as lymph node metastasis and lymphatic involvement positivity. In breast cancer cells, JAM‐A expression status affects malignant potentials including proliferation and migration. Multilayered proteomics revealed that JAM‐A interacts with the amino acid transporter LAT1 in breast cancer cells. JAM‐A regulates the expression of LAT1 and interacts with it on the whole cell membrane, leading to enhanced amino acid uptake to promote tumor growth. Double high expression of JAM‐A and LAT1 predicts poor prognosis in patients with breast cancer. Of note, an antibody against an extracellular domain of JAM‐A suppressed the proliferation of breast cancer cells. Our findings indicate the possibility of JAM‐A‐targeted therapy ideally combined with LAT1‐targeted therapy as a new therapeutic strategy against breast cancer.